(European Society of Cardiology) Serelaxin has failed to meet the primary endpoints of the phase 3 RELAX-AHF-2 trial, according to late breaking results presented for the first time today at Heart Failure 2017 and the 4th World Congress on Acute Heart Failure.
from EurekAlert! - Social and Behavioral Science http://ift.tt/2qvD0dT
No comments:
Post a Comment